Integrative Therapeutics™ Launches Clinically-Proven Pro-Flora™ Women’s Probiotic

Sept. 4, 2012 - PRLog -- Dr. Tori Hudson, ND, Program Director for the Institute of Women’s Health and Integrative Medicine, emphasizes the need for condition-specific probiotic supplementation for women, “Vaginal health concerns are one of the leading reasons women visit healthcare practitioners, and balancing vaginal microflora is essential for maintaining vaginal health. Using a probiotic designed and clinically-studied for treating flora imbalances in the vaginal tract is extremely important.”

Pro-Flora Women’s Probiotic is a combination of two proprietary, clinically-proven Lactobacillus strains, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14, that are supported by more than 20 years of clinical research in supporting urogenital health.*^1-3

A randomized, placebo-controlled clinical trial demonstrated vaginal colonization following oral administration to 64 healthy women. Participants took a capsule containing GR-1 and RC-14, or a matching placebo, once per day for 60 days. The combination was found to significantly and beneficially alter the vaginal flora.* Culture findings confirmed a significant increase in Lactobacilli at day 28 and day 60.* At day 28, individuals who received GR-1 and RC-14 demonstrated improved yeast balance.*¹

This combination is also safe to use with pregnant women, and can be used with conventional options for urogenital health.*²

For more information on the clinically-studied probiotic strains in Pro-Flora Women’s Probiotic, visit https://www.IntegrativeInc.com.

^1. Reid G, Charbonneau D, Erb J, et al. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunol Med Microbiol 2003;35:131–4.
^2. Anukam KC, Osazuwa E, Ahonkhai I, et al. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microbes Infect 2006;8:1450–4.
^3. McMillan A, Dell M, Zellar MP, et al. Disruption of urogenital biofilms by lactobacilli. Colloids Surf B Biointerfaces 2011;86:58–64.

*This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.